Liquid Biopsy Panel Yields Complete Molecular Profile

The primary drivers of ctDNA release into the bloodstream are apoptosis and necrosis of tumor cells. Existing solutions that rely on ctDNA alone are building a profile of the tumor that is biased towards consequences of cell death. Exosomes, in contrast, are actively released by living cells including viable tumor cells.

The MedOncAlyzer 170 panel’s scope includes 170 clinically actionable and functionally relevant gene targets; capture and sequencing of complete coding regions for all targets; 99.9% sensitivity for mutations at allele fractions of equal to or greater than 0.1%; ability to detect RNA-specific events such as gene fusions and splice variants; complete panel coverage from ≥ 0.5mL of the starting material which is plasma; doubles the nucleic acid extracted per mL of sample volume versus ctDNA alone; and 82,000 COSMIC variants interrogated.

Johan Skog, PhD, Chief Science Officer of Exosome Diagnostics, said, “The MedOncAlyzer is the only cancer panel on the market that interrogates information on both RNA and DNA, giving it a higher sensitivity compared to ctDNA assays when profiling early stage and late stage cancers in plasma. The MedOncAlyzer, with its unique ability to co-isolate RNA and DNA, is balanced to produce accurate, highly sensitive identification of rare variants through all stages of disease progression and treatment, including RNA variants that cannot be seen on ctDNA.”

Related Links:
Exosome Diagnostics